This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Birks, E. J. Articles by Yacoub, M. H. Search for Related Content PubMed PubMed Citation Articles by Birks, E. J. Articles by Yacoub, M. H. Pubmed/NCBI databases Substance via MeSH Medline Plus Health Information Heart Transplantation Organ Donation Related Collections Contractile function Other heart failure Apoptosis Cell biology/structural biology Gene expression Gene regulation Growth factors/cytokines Heart failure - basic studies Physiological and pathological control of gene expression Myocardial cardiomyopathy disease Echocardiography CV surgery: transplantation, ventricular assistance, cardiomyopathy Brain Circulation and Metabolism

(Circulation. 2000;102:III-352.)
© 2000 American Heart Association, Inc.

Myocardial Protection and Vascular Biology

Elevated Tumor Necrosis Factor- and Interleukin-6 in Myocardium and Serum of Malfunctioning Donor Hearts

Emma J. Birks, MRCP; Paul B. J. Burton, MBBS; Virginia Owen, PhD; Antony J. Mullen, BSc; Diane Hunt, BSc; Nicholas R. Banner, FRCP; Paul J. R. Barton, PhD; Magdi H. Yacoub, FRS

From the National Heart and Lung Institute at Imperial College School of Medicine, Royal Brompton and Harefield Hospital, Harefield, Middlesex, UK.

Correspondence to Magdi Yacoub, FRS, Professor of Cardiothoracic Surgery, Heart Science Centre, Royal Brompton and Harefield Hospital, Harefield, Middlesex UB9 6JH, UK.

Background—Myocardial dysfunction is a common and important problem in donor hearts. The mechanisms responsible remain unclear. We have studied the cytokines tumor necrosis factor (TNF)- and interleukin-6 (IL-6) in the myocardium and serum from donors with myocardial dysfunction (unused donors) and compared them with donors with good ventricular function (used donors) and patients with advanced heart failure (HF).

Methods and Results—Clinical details and ventricular function were assessed in 46 donors (31 used, 15 unused). Real-time reverse transcription–polymerase chain reaction, Western blotting, and immunocytochemistry were performed on myocardium and immunoassays on serum. TNF- mRNA was 1.6-fold higher in unused than in used donors (P<0.005) and 1.74-fold higher than in 36 patients with HF. IL-6 mRNA was 2.4-fold higher in unused than in used donors (P<0.0001) and 4.67-fold higher than in HF (P<0.0001). Western blotting showed higher TNF- in unused (218.3±6.4, n=4 versus 187.3±5.4, n=3 OD units) than used donors (P<0.05). TNF- expression was localized to cardiac myocytes. Serum TNF- was higher in unused (8.72±1.3 pg/mL, n=13) than in used (6.12±0.8 pg/mL, n=25, P<0.05) donors and HF (4.0±0.4 pg/mL, n=17, P<0.005). Serum TNF- receptors did not differ between unused (4.3±0.8 and 8.6±1.6 ng/mL, n=10) and used (3.5±0.4 and 6.5±1.1 ng/mL, n=24) donors. There was a trend for higher serum IL-6 in unused (16.5±2.9 pg/mL, n=9) compared with used (13.9±1.6 pg/mL, n=26, P=NS) donors.

Conclusions—This study documented an increase in the expression of TNF- and IL-6 in the myocardium of all donor hearts that was more marked in the dysfunctional (unused) donor hearts. This was accompanied by similar changes in the serum. This might have important therapeutic implications.

Key Words: transplantation • myocardium • molecular biology

This article has been cited by other articles:

				A. Amadou, A. Nawrocki, M. Best-Belpomme, C. Pavoine, and F. Pecker Arachidonic acid mediates dual effect of TNF-alpha on Ca2+ transients and contraction of adult rat cardiomyocytes Am J Physiol Cell Physiol, June 1, 2002; 282(6): C1339 - C1347. [Abstract] [Full Text] [PDF]